Ad
related to: what is meropenem used for pneumonia medication list of drugsgoodrx.com has been visited by 100K+ users in the past month
"About 50% of US physicians advise patients consult GoodRx." - Fortune
Search results
Results from the WOW.Com Content Network
Meropenem, sold under the brand name Merrem among others, is an intravenous carbapenem antibiotic used to treat a variety of bacterial infections. [3] Some of these include meningitis, intra-abdominal infection, pneumonia, sepsis, and anthrax.
The following is a list of antibiotics. The highest division between antibiotics is bactericidal and bacteriostatic . Bactericidals kill bacteria directly, whereas bacteriostatics prevent them from dividing.
Meropenem/vaborbactam, sold under the brand name Vabomere among others, is a combination medication used to treat complicated urinary tract infections, complicated abdominal infections, and hospital-acquired pneumonia. [2] [3] [4] It contains meropenem, a beta-lactam antibiotic; and vaborbactam, a beta-lactamase inhibitor. [4]
The carbapenems imipenem and meropenem are recommended by the American Thoracic Society and the Infectious Disease Society of America as one of several first-line therapy options for people with late-onset hospital-acquired or ventilator-associated pneumonia, especially when Pseudomonas, Acinetobacter, or extended spectrum beta-lactamase ...
This is a list of common β-lactam antibiotics—both administered drugs and those not in clinical use—organized by structural class. Antibiotics are listed alphabetically within their class or subclass by their nonproprietary name. If an antibiotic is a combination drug, both ingredients will be listed.
For ceftriaxone, the color of solutions can range from light yellow to amber, depending on the length of storage, concentration, and diluent used. [30] [31] A study found that meropenem concentrations dropped to 90% of the initial concentration at 7.4 hours at 22°C and 5.7 hours at 33°C, indicating degradation over time. [29]
Many studies use media with 1 to 2 mg/L of imipenem. However, bacteria that produce OXA-48 or OXA-181 result in low-level resistance, which cannot be detected efficiently due to the high concentration. [37] Therefore, more recent screening media use broth containing 0.5–1 mg/L imipenem or 0.5 mg/L ertapenem. The downsides to this approach ...
The FDA said the drug was “nonapprovable”, but did not refer to specific safety concerns about the product. The company will have to conduct new studies and clinical trials, lasting an estimated two more years, to prove the drug treats community-acquired pneumonia, bacterial sinusitis, chronic bronchitis, and skin infections.